Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Call to be held on May 27, 2024 at 8:30 AM (IST) on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2024.
Please pre-register by clicking hereor copy and paste the following link in your browser
https://bit.ly/4bGnlir
Earnings Presentation will be available on the Company's website link : Earnings Presentationpost results announcement
Digitally signed by BADDIGAM ADI REDDY
Date: 2024.05.17 11:24:07 +05'30'
Attachments
Original Link
Original Document
Permalink
Disclaimer
Aurobindo Pharma Ltd. published this content on
17 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
17 May 2024 13:21:37 UTC.
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
AUROBINDO PHARMA 
